TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07849231: A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

Sponsor: Damora Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 250 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT07849231 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07849231 Rescue Dossier →